tirzepatide emc Flex-Dose 1 mL Injectable 10 mg/mL 1 approach to weight loss that minimizes side effects Learn more about Tirzepatide_Industry News_Senova

During periods of drug shortage, the FDA permits 503A compounding pharmacies to produce versions of the drug to meet patient demand

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management in adults (Mounjaro) and chronic weight management in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity (Zepbound)

At our Atlanta, GA - Norcross clinic, providers review medical history, lab data, current medications, and individual goals before determining whether Tirzepatide is appropriate

Compound Semaglutide (Injection) WARNING: RISK OF THYROID C-CELL TUMORS BLACK BOX WARNING: As an alternative to FDA-approved branded products, where appropriate, a provider may prescribe a compounded drug, which is prepared by a state-licensed sterile compounding pharmacy partner

These are not unreasonable questions

In a review of racial and ethnic differences in obesity outcomes of lifestyle, surgical, and pharmacological interventions published between 2000 and 2022, lower efficacy of lifestyle and surgical interventions was commonly identified among Black compared with White participants (with no or smaller differences for Hispanic compared with White participants)